ファーマナビゲーター　DIC編

出版社： メディカルレビュー社
著者：
発行日： 2014-11-10
分野： 臨床医学：一般  >  薬物療法
ISBN： 9784779213496
シリーズ： ファーマナビゲーター
電子書籍版： 2014-11-10 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

3,850 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,925 円(税込)

購入する
特記事項：

商品紹介

播種性血管内凝固症候群（ＤＩＣ）の薬理作用をはじめ、分類、病態と治療、処方の実際を解説。トピックス、Ｑ＆Ａも掲載する。略語一覧、和文・欧文索引付き。

目次

  • ファーマナビゲーター　DIC編

    ―目次―

    Chapter 1　薬理作用
    　1．概念と最近の進展：DICとは（DICのメカニズム）

    Chapter 2　DICの分類
    　1．時間経過に基づいた分類
    　2．凝固と線溶のダイナミズムからみた分類

    Chapter 3　病態と治療
    　1．病態基盤と病型
    　2．診断基準
    　3．治療総論（従来の治療と最新の治療）

    Chapter 4　処方の実際
    　1．造血器悪性腫瘍とDIC
    　2．固形癌とDIC
    　3．外科のDIC（リスクの高い手術）
    　4．救急領域のDIC
    　5．新生児領域のDIC
    　6．産科・婦人科領域のDIC
    　7．DIC治療のEBM

    Chapter 5　トピックス
    　1．PAMPs/DAMPs
    　2．類洞閉塞症候群（SOS）
    　3．ヘパリン起因性血小板減少症（HIT）
    　4．プロカルシトニン
    　5．溶血性尿毒症症候群（HUS）
    　6．ADAMTS 13と血栓性血小板減少性紫斑病（TTP）
    　7．特発性肺線維症（IPF）
    　8．妊娠高血圧症候群
    　9．抗リン脂質抗体症候群（APS）
    　10．敗血症に伴うDIC
    　
    Chapter 6　Question & Answer
    　1．いわゆる「線溶抑制型」DICと「線溶亢進型」DICでは、
    　　　DIC治療薬の使い分けが必要でしょうか
    　2．SIRSはDICを合併しやすいと聞きます。
    　　　SIRSという疾患概念について教えて下さい
    　3．敗血症患者におけるDIC治療は、予後の改善をもたらしますか
    　4．造血幹細胞移植に伴う合併症に対して、抗凝固療法は
    　　　どの程度期待できますか
    　5．DPCを念頭においた場合、DICの治療戦略は
    　　　どうあるべきでしょうか
    　6．小児に対するDIC治療薬の選択とそのエビデンスを
    　　　教えて下さい
    　7．DICによって腎機能が傷害された場合のDIC治療について、
    　　　どのような点に留意すればよいでしょうか
    　8．急性期侵襲病態ではミトコンドリアはどのような
    　　　役割をしているのでしょうか

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter 1 薬理作用

P.30 掲載の参考文献
1) Davie EW, Fujikawa K, Kisiel W : The coagulation cascade : initiation, maintenance, and regulation. Biochemistry 30 : 10363-10370, 1991
PubMed
2) Delvaeye M, Conway EM : Coagulation and innate immune responses : can we view them separately? Blood 114 : 2367-2374, 2009
PubMed
3) Matzinger P : Tolerance, danger, and the extended family. Annu Rev Immunol 12 : 991-1045, 1994
PubMed
4) Ito T, Kawahara K, Nakamura T et al : High-mobility group box 1 protein promotes development of. microvascular thromosis in rats. J Thromb Haemeost 5 : 109-116, 2007
 
5) Nakahara M, Ito T, Kawahara K et al : Recornbinant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS One 30 : e75961, 2014
 
6) Abeyama K, Stern DM, Ito Y et al : The N-terminal domain of thrombomodulin sequesters high-mobility grope-B 1 protein, a novel anti-inflammatory mechanism. J Clin fnvest 115 : 1267-1274, 2005
 
7) Shi CS, Shi GY, Hsiano HM et al : Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysacchared-induced inflammatory response. Blood 112 : 3661-3670, 2008
 

Chapter 2 DICの分類

P.44 掲載の参考文献
1) Wada H : Disseminated intravascular coagulation. Clin Chim Acta 344 : 13-21, 2004
PubMed
2) Wada H, Matsumoto T, Hatada T : Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol 5 : 643-652, 2012
PubMed
3) 和田英夫 : 播種性血管内凝固症候群 (DIC). 三輪血液病学 (浅野茂隆, 池田康夫, 内山卓監修). 文光堂, 東京, 2005, p 1743-1752
 
4) 青木延雄, 長谷川淳 : DIC診断基準の『診断のための補助的検査成績, 所見』の項の改訂について. 厚生省特定疾患血液凝固異常症調査研究班平成4年度業績報告集. 1988, p37-41
 
5) Taylor FB Jr, Toh CH, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001
 
6) Gando S, Iba T, Eguchi Y et al : A multicenter, prospective validation of disseminated intra vascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med 34 : 625-631, 2006
 
7) Gando S, Wada H, Kim HK et al : Comparison of disseminated intravascular coagulation in trauma with coagulopathy of trauma/acute coagulopathy of trauma-shock. J Thromb Haemost 10 : 2593-2595, 2012
 
8) Wada H, Wakita Y, Nakase T et al : Outcome of disseminated intravascular coagulation in relatioll to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 74 : 848-852, 1995
 
9) Wada H, Minamikawa K, Wakita Y et al : Hemostatic study before onset of disseminated intravascular coagulation, Am J Hematol 43 : 190-194, 1993
PubMed
10) Wada H, Wakita Y, Nakase T et al : Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 51 : 255-260, 1996
PubMed
P.57 掲載の参考文献
1) 金沢大学血液内科・呼吸器内科 : 播種性血管内凝固症候群 (DIC). http://www.3nai.jp/weblog/entry/24539.html
 
2) Levi M, Ten Cate H : Disseminated intravascular coagulation, N Engl J Med 341 : 586-592, 1999
PubMed
3) Taylor FB Jr, Toh CH, Hoots WK et al : Towards definition, clinical and laboratory criteria. and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001
 
4) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 : 77-113, 2009
 
5) 林朋恵, 朝倉英策 : 播種性血管内凝固症候群の病態・診断. わかりやすい血栓と止血の臨床 (日本血栓止血学会編). 南江堂, 東京, 2011, p190-194
 
6) Menell JS, Cesarman GM, Jacovina AT et al : Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340 : 994-1004 , 1999
PubMed
7) Madoiwa S, Someya T, Hironaka M et al : Amexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis. Thromb Res 119 : 229-240, 2007
PubMed

Chapter 3 病態と治療

P.66 掲載の参考文献
1) 金沢大学血液内科・呼吸器内科 : 播種性血管内凝固症候群 (DIC). http://www.3nai.jp/weblog/entry/24539.html
 
2) Matthay MA. Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 344 : 759-762, 2001
PubMed
3) Menell JS, Cesarman GM, Jacovina AT et al : Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340 : 994-1004, 1999
PubMed
4) Brown JE, Olujohungbe A, Chang J et al : All-trans retinoic acid (ATRA) and tranexamic acid : a potentially fatal combination in acute promyelo. cytic leukaemia. Br J Haematol 110 : 1010-1012, 2000
 
5) Pogliani EM, Rossini F. Casaroli I et al : Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy. Br J Haematol 97 : 228-230, 1997
 
6) Tsukada N, Wada K, Aoki S et al : Induction therapy with all-trans retinoic acid for acute promyelocytic leukemia : a clinical study of 10 cases, including a fatal case with thromboembolism. Intern Med 35 : 10-14, 1996
PubMed
7) Hashimoto S, Koike T, Tatewaki W et al : Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage, Leukemia 8 : 1113-1115, 1994
PubMed
8) Mahendra P, Keeling DM, Hood IM et al : Fatal thromboembolism in acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin. Clin Lab Haematol 18 : 51-52, 1996
PubMed
9) Kocak U, GUrsel T. OztUrk G, Kantarci S : Thrombosis during all-transretinoic acid therapy in a child with acute promyelocytic leukemia and factor VQ 506 mutation. Pediatr Hematol Oncol 17 : 177-180, 2000
 
10) Breen KA, Grimwade D, Hunt BJ : The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 156 : 24-36, 2012
PubMed
11) Saito H, Maruyama I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 : 31-41, 2007
PubMed
12) Ikezoe T, Yang J, Nishioka C et al : Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells. Exp Hematol 40 : 457-465, 2012
PubMed
13) Yang J, Ikezoe T, Nishioka C et al : Thrombomodulin-induced differentiation of acute myelomonocytic leukemia cells via JNK signaling. Leuk Res 36 : 625-633, 2012
PubMed
14) Ikezoe T, Togitani K, Komatsu N et al : Successfui treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 45 : 783-785, 2010
 
15) Sakai M, Ikezoe T, Bandobashi K et al : Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 45 : 803-805, 2010
PubMed
16) Nomura S, Ozasa R, Nakanishi T et al : Can recombinant thrombomodulin play a preventive role for VOD after haematopoietic stem cell transplantation? Thromb Haemost 105 : 1118-1120, 2011
 
17) Inoue Y, Kosugi S, Miura I et al : Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Thromb Res 127 : 603-604, 2011
PubMed
18) Nakamura D, Yoshimitsu M, Kawada H et al : Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post anogeneic hematopoietic SCT. Bone Marrow Transplant 47 : 463-464, 2012
PubMed
P.78 掲載の参考文献
1) Wada H : Disseminated intravascular coagulation. Clin Chim Acta 344 : 13-21, 2004
PubMed
2) Wada H, Matsumoto T, Hatada T : Diagnostic criteria and laboratory tests for disseminated intravascular coagulation. Expert Rev Hematol 5 : 643-652, 2012
PubMed
3) 中川雅夫 : 厚生省特定疾患血液系疾患調査研究班, 血液凝固異常症分科会, 平成10年度研究業績報告書, 1999, p 57-72
 
4) Taylor Jr FB, Toh CH, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation-On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 86 : 1327-1330, 2001
 
5) 青木延雄, 長谷川淳 : DIC診断基準の「診断のための補助的検査成績, 所見』の項の改訂について. 厚生省特定疾患血液凝固異常症調査研究班, 平成4年度業績報告集, 1988, p37-41
 
6) 松田保 : DICの臨床-播種性血管内凝固の臨床-. 新興医学出版, 東京, 1997, p1
 
7) Muller-Berghaus G, ten Cate H, Levi M : Disseminated intravascular coagulation : Clinical spectrum and established as well as rlew diagnostic approaches. Thromb Haemost 82 : 706-712, 1999
PubMed
8) Bone RC : Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268 : 3452-3455, 1992
PubMed
9) Gando S, Iba T, Eguchi Y et al. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group : A multicenter, prospective validation of disseminated irltravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria, Crit Care Med 34 : 625-631, 2006
 
10) Colman RW, Robby SJ, Minna JD : Disseminated intravascular coagulatiOn (DIC) : an approach, Am J Med 52 : 679-689, 1972
 
11) Al-Mondhiry H : Disseminated intravascular coagulation : experience in a major cancer center, Thromb Diath Haemorrh 34 : 181-193, 1975
 
12) 松田保 : 播種性血管内凝固 (DIC). 臨床血液 17 : 1139-1152, 1976
 
13) Siegal T, Seligsohn U, Aghai E et al : Clinical and laboratory aspects of disseminated intravascular coagulation (DIC) : a study of 118 cases. ThrombHaemosts 39 : 122-134, 1978
PubMed
14) Spero JA, Lewis JH, Hasiba U : Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemosts 43 : 28-33, 1980
PubMed
15) 松田保, 朝倉英策, 山崎雅英ほか : DIC診断基準の問題点 : フィブリノゲンとプロトロンビン時間の問題点について, 厚生省特定疾患血液凝固異常症調査研究班, 平成4年度業績報告集, 1993, p 24-30
 
16) Toh CH, Downey C : Performance and prognostic importance of a new clinical and laboratory scoring system fdr identifying non-overt disseminated intravascular coagulation. J Blood Coagul Fibrinolysis 16 : 69-74, 2005
 
17) Hayakawa M, Gando S, Hoshino H : A Prospective comparison of new Japanese criteria for disseminated intravascular coagulation : new Japanese criteria versus ISTH criteria. Clin Appl Thromb Hemost 13 : 172-181, 2007
 
18) Egi M, Morimatsu H, Wiedermann CJ et al : Non-overt disseminated intravascular coagulation scoring for critically ill patients : The impact of antithrombin levels, Thromb Haemost 101 : 696-705, 2009
 
19) Oh D, Jang MJ, Lee SJ et al : Evaluation of modified non-overt DIC criteria on the prediction of poor outcome in patients with sepsis. Thromb Res 126 : 18-23, 2010
PubMed
20) Wada H, Hatada T, Okamoto K et al : Japanese Society of Thrombosis Hemostasis/DIC subcommittee, : Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC, Am J Hematol 85 : 691-694, 2010
PubMed
P.90 掲載の参考文献
1) Wada H : Disseminated intravascular coagulation. Clin Chim Acta 344 : 13-21, 2004
PubMed
2) Warren BL, Eid A, Singer P et al : High-dose antithrombin in severe sepsis. A randomized controlled trial. JAMA 286 : 1869-1878, 2001
PubMed
3) Bernard GR, Vincent JL, Laterre PF et al ; Efficacy and safety of recombinant human protein C for severe sepsis, New Engl J Med 8 : 699-709, 2001
PubMed
4) Aoki N, Matsuda T, Saito H et al : A comparative double blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation, Int J Hematol 75 : 540-547, 2002
 
5) Abraham E, Reinhart K, Opal S et al : Effucacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis : a randomized controlled trial. JAMA 290 : 238-247, 2003
 
6) Saito H, Maruyalna I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 : 31-41, 2007
PubMed
7) Levi M, Toh CH, Thachil J et al : Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 145 : 24-33, 2009
PubMed
8) Wada H, Asakura H, Okamoto K et al : Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 125 : 6-11, 2010
PubMed
9) Di Nisio M, Baudo F, Cosmi B et al : on behalf of the Italian Society for Thrombosis and Haemostasis, Diagnosis and treatment of disseminated intravascular coagulation : Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET), Thromb Res 129 : e177-e184, 2012
 
10) Wada H, Thachil J, Di Nisio M et al : Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 11 : 761-767, 2013
 
11) Kienast J, Juers M, wiedermann CJ et al : Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4 ; 90-97, 2005
 
12) Wiedermann CJ, Kaneider N : A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sePsis. Blood Coagul Fibrinolysis 17 : 521-526, 2006
PubMed
13) Iba T, Saito D, Wada H et al : Efficacy bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation : A prospective multicenter survey. Thromb Res 130 : e129-e133, 2012
PubMed
14) 神前五郎, 神林純一, 平山亮夫ほか : DICに対するFOYの治療効果に関する研究-多施設比較臨床試験-. 医学のあゆみ 124 : 144-154, 1983
 
15) 柴田昭, 高橋芳右, 服部晃ほか : DICに対するFUT-175注の治療効果-多施設比較臨床試験による検討-. 臨床と研究 65 : 921-940, 1988
 
16) Polderman KH, Girbes AR : Drug intervention trials in sepsis : divergent results. Lancet 363 : 1721-1723, 2004
PubMed
17) Sakuragawa N, Hasegawa H, Maki M et al : Clinical evaluation of lowmolecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) -a multicenter co-operative double-blind trial in comparison with heparin, Thromb Res 72 : 475-500, 1993
 
18) Nishiyama T, Matsukawa T, Hanaoka K : Is protease inhibitor a choice for the treatment of pre-or mild disseminated intravascular coagulation? Crit Care Med 28 : 1419-1422, 2000
PubMed
19) Hsu JT, Chen HM, Chiu DF et al : Efficacy of gabexate mesilate on disseminated intravascular coagulation as a complication of infection developing after abdominal surgery. J Formos Med, Assoc 103 : 678-684, 2004
PubMed
20) Yamakawa K Fujimi S, Mohri T et al : Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis : a historical control study. Crit Care 15 : R123, 2011
PubMed
21) Vincent JL, Bernard GR, Beale R et al : Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE : further evidence for survival and safety and implications for early treatment. Crit Care Med 33 : 2266-2277, 2005
PubMed
22) Abraham E, Laterre PF, Garg R et al : Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death, N Engl J Med 353 : 1332-1341, 2005
 
23) Ranieri VM, Thompson BT, Barie PS et al : Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366 : 2055-2064, 2012
PubMed

Chapter 4 処方の実際

P.98 掲載の参考文献
1) Wada H, Wakita Y, Nakase T, et al : Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 74 : 848-852, 1995
 
2) 竹迫直樹 : 造血器悪性腫瘍に伴うDICの治療. Thromb Med 2 : 387-390, 2012
Medical*Online
3) 川杉和夫 : 造血器悪性腫瘍に合併したDICに対するrTM製剤の効果. 臨病理レビュー 147 : 181-187, 2011
Medical*Online
P.106 掲載の参考文献
1) 中川雅夫 : 本邦における播種性血管内凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患・血液系疾患調査研究班血液凝固異常症分科会平成10年度研究業績報告書, 1999, p57-64
 
2) Weitz IC, Israel VK, Waisman JR et al : Chemotherapy-induced activation of hemostasis : effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost 88 : 213-220, 2002
PubMed
3) 朝倉英策, 林朋恵, 前川実生ほか : DICの治療戦略. 日内会誌 98 : 1640-1647, 2009
 
4) Takahashi H, Tatewaki W, Wada K et al : Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am J Haematol 33 : 90-95, 1990
 
5) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 : 77-113, 2009
 
P.112 掲載の参考文献
1) 丸藤哲, 池田寿昭, 石倉宏恭ほか : 急性期DIC診断基準. 第二次多施設共同前向き試験結果報告, 日救急医会誌 18 : 237-272, 2007
 
2) 丸山征郎, 坂田洋一, 和田英夫ほか : 科学的根拠に基づいた感染症に伴 うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 ; 77-113, 2009
 
P.118 掲載の参考文献
1) Gando S : Disseminated intravascular coagulation in trauma patients. Semin Thromb Haemost 27 : 585-591, 2001
 
2) Gando S, Sawamura S, Hayakawa M : Trauma, shock, and disseminated intravascular coagulation. Ann Surg 254 : 10-19, 2011
 
3) Hoffman M, Monroe III DM : A cell-based model of hemostasis, Thromb Haemost 85 : 958-965, 2001
 
4) Sawamura A, Hayakawa M, Gando S et al : Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality, Thromb Res 124 : 608-613, 2009
PubMed
5) Dunbar NM, Chandler WL : Thrombin generation in trauma patients, Transfusion 49 : 2652-2660, 2009
PubMed
6) CRASH-2 collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH-2) : a randomized, placebo-controlled trial. Lancet 376 : 23-32, 2010
PubMed
7) CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients : an exploratory analysis of the CRASH-2 randomized controlled trial. Lancet 377 : 1096-1101, 2011
PubMed
P.129 掲載の参考文献
1) 白幡聡, 白川嘉継 : 新生児のDIC. 血栓止血誌 17 : 245-253, 2006
 
2) 椎木みどり, 有吉宣明, 中村外士雄, 白幡聡 : 新生児の凝固・線溶阻止因子の動態. 臨床血液 32 : 758-765, 1991
 
3) 下野昌幸, 浦野元, 高尾伸也ほか : 新生児期のプロテインCとプロテインSの動態-ビタミンK投与例での検討, 日本新生児誌 26 : 503-510, 1990
 
4) 白川嘉継, 中村外士雄, 白幡聡, 山岸稔 : 新生児期の血漿ヘパリンコファクター II値. 日本新生児誌 26 : 727-731, 1990
 
5) Tay SP, Cheong SK, Bob NY : Circulating tissue factor, tissue factor pathway inhibitor and D-dimer in umbilical cord blood of normal term neonates and adult plasma. Blood Coagul Fibrinolysis 14 : 125-129 2003
 
6) Gomez R, Romero R, Ghezzi F et al : The fetal inflammatory response syndrome. Am J Obstet Gynecol 179 : 194-202, 1998
PubMed
7) 丸山征郎 : DIC発現の新規メディエーターと臨床への応用を探る, DIC治療の新たなるストラテジー (丸藤哲編). 東京, 先端医学社, 2004, p31-35
 
8) 岡島研二 : DICおよび重症感染症のアンチトロンビン III 濃縮製剤による治療. Biomed Perspect 2 : 75-82, 1993
 
9) 丸山征郎, 鈴木宏治 : 血管内皮細胞の抗血栓分子トロンボモジュリン (TM) による循環維持機構の解明と遺伝子組み換えTMによる血栓制御の臨床展開. 最新医学 64 : 264-289, 2009
 
P.138 掲載の参考文献
1) 小林隆夫 : 産科ショックとDIC (小林隆夫, 水上尚典, 白幡聡編). 周産期の出血と血栓症. 金原出版東京, 2004, p168-182
 
2) 小林隆夫 : 産科DICの特徴とDICスコア, DIC-診断・治療の最前線. 医学のあゆみ 238 : 77-82, 2011
 
3) 木村聡, 平井久也, 内田季之ほか : DIC初発羊水塞栓症と心肺虚脱初発羊水塞栓症の血清マーカーの比較 日本産婦人科・新生児血液学会誌, 20 : S55-S56, 2010
 
4) 小林隆夫 : 産科異常出血, DICの薬物療法. 産婦の実際 62 : 153-161, 2013
 
5) Kobayashi T, Nakabayashi M, Yoshioka A et al : Recombinant activated factor VII (rF VII a/NovoSeven(R)) in the management of severe postpartum haemorrhage : initial report of a multicentre case series in Japan. Int J Hematol 95 : 57-63, 2012
 
6) 小林隆夫 : 遺伝子組換え活性型血液凝固第VII因子製剤, Thrombosis Medicine 2 : 363-369, 2012
Medical*Online
7) 真木正博, 寺尾俊彦, 池ノ上克 : 産科DICスコア. 産婦治療 50 : 119-124, 1985
 
8) 野田洋一 : DICおよびDICの処置. 日産婦会誌 61 : N6-N10, 2009
 
P.145 掲載の参考文献
1) Wada H : Disseminated intravascular coagulation. Clin Chim. Acta 344 : 13-21, 2004
PubMed
2) Levi M, Toh CH, Thachil J et al : Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 145 : 24-33, 2009
PubMed
3) Wada H, Asakura H, Okamoto K et al : Expert consensus for the treatment of disseminated intravascular coagulation in Japan, Thromb Res 125 : 6-11, 2010
PubMed
4) Di Nisio M, Baudo F, Cosmi B et al : on behalf of the Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation : Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET), Thromb Res 129 : e177-e184, 2012
 
5) Wada H, Thachil J, Di Nisio M et al : The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis : Guidance for diagnosis and treatment of DIC frorn harmonization of the recommendations from three guidelines. J Thromb Haemost 11 : 761-767, 2013
 
6) Guyatt GH, Oxman AD, Vist GE et al : GRADE Working Group. GRADE : an emerging consensus on rating quality of evidence and strength of recommendations, BMJ 336 : 924-926, 2008
 
7) Geerts WH, Pineo GF, Heit JA et al : Prevention of Venous Thromboembolism : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 : S338-S 400, 2004
 

Chapter 5 トピックス

P.157 掲載の参考文献
1) Matzinger P : The danger model : a renewed sense of self. Science 296 ; 301-305, 2002
 
2) Kono H, Rock KL : How dying cells alert the immune system to danger. Nat Rev Immunol 8 : 279-289, 2008
PubMed
3) Engelmann B, Massberg S : Thrombosis as an intravascular effector of innate immunity. Nat. Rev Immunol 13 : 34-45, 2013
PubMed
4) Clark SR, Ma AC, Tavener SA et al : Platelet TLR 4 activates rleutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13 : 463-469, 2007
 
5) Massberg S, Grahl L, von Bruehl ML et al : Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16 : 887-896, 2010
PubMed
6) Ito T, Kawahara K, Nakamura T et al : High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 5 : 109-116, 2007
PubMed
7) Faust SN, Levin M, Harrison OB et al : Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345 : 408-416, 2001
PubMed
8) Saito H, Maruyama I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 : 31-41, 2007
PubMed
9) Ito T, Maruyama I : Thrombomodulin : protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 9 : 168-173, 2011
PubMed
10) Abeyama K, Stern DM, Ito Y et al : The N-terminal domain of thrombomodulin sequesters high-mobility group-B 1 protein, a novel antiinnammatory mechanism. J Clin Invest 115 : 1267-1274, 2011
 
11) Ito T, Kawahara K, Okamoto K et al : Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28 : 1825-1830, 2008
PubMed
12) Shi CS, Shi GY, Hsiao SM et al : Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced infiammatory response. Blood 112 : 3661-3670, 2008
 
P.168 掲載の参考文献
1) DeLeve LD, Ito Y, Bethea NW et al : Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol 284 : G1045-G1052, 2003
PubMed
2) Braet F, Wisse E : Structural and functional aspects of liver sinusoidal endothelial cell fenestrae : a review. Comp Hepatol 1 : 1-17, 2002
 
3) Coppell JA, Richardson PG, Soiffer R et al : Hepatic veno-occlusive disease following stem cell transplantation : incidence, clinical course, and outcome. Biol Blood Marrow Transplant 16 : 157-168, 2010
PubMed
4) Carreras E, Bertz H, Arcese W et al : Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation : a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92 : 3599-3604, 1998
PubMed
5) Carreras E, Diaz-Beya M, Rosiiol L et al : The incidence of veno-occlusive disease fOllowing allogeneic hematopoietic stern cell transplantation has diminished and the outcome improved over the last decade, Biol Blood Marrow Transplant 17 : 1713-1720, 2011
 
6) McDonald GB, Hinds MS, Fisher LD et al : Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients. Ann Intern Med 118 : 255-267, 1993
PubMed
7) Jones RJ, Lee KS, Beschorner WE et al : Venoocclusive disease of the liver following bone marrow transplantation, Transplantation 44 : 778-783, 1987
PubMed
8) Carreras E : Veno-occlusive disease of the liver after hemopoietic cell transplantation, Eur J Haematol 64 : 281-291, 2000
PubMed
9) Carreras E, Diaz-Ricart M : The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant 46 : 1495-1502, 2011
PubMed
10) Ruutu T, Eriksson B, Remes K et al : Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 100 : 1977-1983, 2002
PubMed
11) Attal M, Huguet F, Rubie H et al : Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin : aprospective, randomized trial. Blood 79 : 2834-2840, 1992
 
12) Bearman SI, Lee JL, Baron AE et al. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 89 : 1501-1506, 1997
PubMed
13) 小池隆志, 矢部普正 : 移植後肝VODに対するdefibrotideの効果, 血液内科 65 : 703-709, 2012
 
14) Saito H, Maruyama I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 : 31-41, 2007
PubMed
P.180 掲載の参考文献
1) Warkentin TE : Drug-induced immune-mediated thrombocytopenia--from purpura to thrombosis. N Engl J Med 356 : 891-893, 2007
PubMed
2) Linkins LA, Dans AL, Moores LK et al : Treatment and prevention of heparin-induced thrombocytopenia : Antithrombotic therapy and prevention of thrombosis, 9th ed : American college of chest physicians evidence-based clinical practice guidelines, Chest 141 : e495S-e530S, 2012
PubMed
3) Amiral J, Bridey E Dreyfus M et al : Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68 : 95-96, 1992
 
4) Greinacher A, Potzsch B, Amiral J et al : Heparin-associated thrombocytopenia : Isolation of the antibody and characterization of a multimolecular pf 4-heparin complex as the major antigen. Thromb Haemost 71 : 247-251, 1994
 
5) Miyata S : Heparin-induced thrombocytopenia. Vox Sang 4 : 167-173, 2009
 
6) Reilly MP, Taylor SM, Hartman NK et al : Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through fcgammariia. Blood 98 : 2442-2447, 2001
 
7) Warkentin TE, Sheppard JA, Moore JC et al : Studies of the immune response in heparin-induced thrombocytopenia. Blood 113 : 4963-4969, 2009
PubMed
8) Rauova L, Hirsch JD, Greene TK et al : Monocyte-bound pf 4 in the pathogenesis of heparin-induced thrombocytopenia, Blood 116 : 5021-5031, 2010
 
9) Cines DB, Tomaski A, Tannenbaum S : Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 316 : 581-589, 1987
PubMed
10) Arepally GM, Mayer IM : Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98 : 1252-1254, 2001
PubMed
11) Warkentin TE, Elavathil LJ, Hayward CP et al : The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 127 : 804-812, 1997
PubMed
12) Greinacher A, Eichler P, Lubenow N et al : Heparin-induced thrombocytopenia with thromboembolic complications : Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aptt range. Blood 96 : 846-851, 2000
PubMed
13) Greinacher A, Kohlmann T, Strobel U et al : The temporal profile of the anti-pf 4/heparin immune response. Blood 113 : 4970-4976, 2009
 
14) Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytoperlia. N Engl J Med 344 : 1286-1292, 2001
PubMed
15) Warkentin TE, Kelton JG : Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 : 502-506, 2001
PubMed
16) Warkentin TE, Bernstein RA : Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 34811067-1069, 2003
PubMed
17) Linkins LA, Warkentin TE : Heparin-induced thrombocytopenia : Realworld issues. Semin Thromb Hemost 37 : 653-663, 2011
 
18) Warkentin TE, Roberts RS, Hirsh J, Kelton JG : Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome : A nested cohort study. Chest 127 : 1857-1861, 2005
PubMed
19) Warkentin TE, Makris M, Jay RM, Kelton JG : A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 121 : 632-636, 2008
PubMed
20) Lo GK, Juhl D, Warkentin TE et al : Evaluation of pretest clinical score (4t's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4 : 759-765, 2006
 
21) Pouplard C, Gueret P, Fouassier M et al : Prospective evaluation of the '4ts' score and particle gel immunoassay specific to heparin/pf 4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 5 : 1373-1379, 2007
 
22) Warkentin TE, Sheppard JA. Horsewood P et al : Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96 : 1703-1708, 2000
PubMed
23) Greinacher A, Juhl D, Strobel U et al : Heparin-induced thrombocytopenia : A prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the igg, igm, and iga classes. J Thromb. Haemost 5 : 1666-1673, 2007
PubMed
24) Warkentin TE, Sheppard JI, Moore JC et al : Quantitative interpretation of optical density measurements using pf 4-dependent enzyme-immunoassays. J Throb Haemost 6 : 1304-1312, 2008
 
25) Greinacher A, Ittermann T, Bagemuhl J et al : Heparin-induced thrombocytopenia : Towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 8 : 2025-2031, 2010
PubMed
26) Demma LJ, Winkler AM, Levy JH : A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. A nesthesia and analgesia 113 : 697-702, 2011
 
27) Kawano H, Yamamoto H, Miyata S et al : Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients. Br J Haematol 154 : 378-386, 2011
PubMed
28) Maeda T, Noguchi T, Saito S et al : Impact of heparin-induced thrombocytopenia on acute coronary artery thrombosis in patients undergoing percutaneous coronary intervention. Thromb Haemost, 2014 (in press)
 
29) Miyata S, Yamamoto H, Kamei M et al : Heparin-induced thrombocytopenia cinical studies and the efficacy of argatroban in japan. Semin Thromb Hemost 34 (suppl 1) : 37-47, 2008
 
30) Warkentin TE, Greinacher A, eds : Heparin-induced thrombocytopenia. 5th ed, CRC press, 2013
 
31) Warkentin TE, Levine MN, Hirsh J et al : Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 : 1330-1335, 1995
PubMed
32) Greinacher A, Warkentin TE : The direct thrombin inhibitor hirudin. Thromb Haemost 99 : 819-829, 2008
PubMed
P.188 掲載の参考文献
1) Oberhoffer M, Stonans I, Russwurm S et al : Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 134 : 49-55, 1990
 
2) Dandona P, Nix D, Wilson MF et al : Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79 : 1605-1608, 1994
PubMed
3) Assicot M, Gendrel D, Carsin H et al : High serum procal citonin concentration in patients with sepsis and infection. Lancet 341 : 515-518, 1993
 
4) 久志本成樹 : プロカルシトニンは何をし, その上昇の意味するものは? 日集中医誌 18 : 330-333, 2011
 
5) Luzzani A, Polati E, Dorizzi R et al : Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 31 : 1737-1741, 2003
 
6) Tang BMP, Eslick GD, Craig JC et al : Accuracy of procalcitonin for sepsis diagnosis in critically ill patients : systematic review and meta-analysis. Lancet Infect Dis 7 : 210-217, 2007
 
7) Delevaux I, Andre M, Colombier M et al : Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62 : 337-340, 2003
PubMed
8) 日本集中治療医学会Sepsis Registry委員会 : 日本集中治療医学会第1回Sepsis Registry調査-2007年の重症敗血症および敗血症性ショックの診療結果報告-. 日集中医誌 20 : 329-334 , 2013
 
9) Christ-Crain M, Jaccard-Stolz D, Bingisser R et al : Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections : cluster-randomised, single-blinded intervention trial. Lancet 363 : 600-607, 2004
PubMed
10) Nobre V, Harbarth S, Graf JD et al : Use of procalcitonin to shorten antibiotic treatment duration in septic patients : a randomized trial. Am J Respir Crit Care Med 177 : 498-505, 2008
PubMed
11) Bouadma L, Luyt CE, Tubach F et al : Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial) : a multicentre randomised controlled trial. Lancet 375 : 463-474, 2010
 
12) Dellinger RP, Levy MM, Rhodes A et al : Surviving sepsis campaign : international guidelines for management of severe sepsis and septic shock : 2012. Crit Care Med 41 : 580-637, 2013
PubMed
13) Heyland DK, Johnson AP, Reynolds SC et al : Procalcitonin for reduced antibiotic exposure in the critical care setting : a systematic review and an economic evaluation. Crit Care Med 39 : 1792-1799, 2011
 
14) Jenserl JU, Hein L, Lurldgren B et al : Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit : a randornized trial, Crit Care Med 39 : 2048-2058, 2011
 
15) Becker KL, Snider R, Nylen ES : Procalcitonin assay in systemic inflammation, infection, and sepsis : clinical utility and limitations. Crit Care Med 36 : 941-952, 2008
PubMed
P.200 掲載の参考文献
1) Moake J : Thrombotic microangiopathies. N Engl J Med 347 : 589-600, 2002
PubMed
2) 香美祥二, 岡田浩一, 要伸也ほか : 非典型型溶血性尿毒症症候群 診断基準. 日腎学会誌 55 : 91-93, 2013
 
3) Proulx F, Seidman E, Mariscalco MM et al : Increased circulating levels of lipopolysaccharide binding protein in children with Escherichia coli O157 : H7hemorrhagic colitis and hemolytic uremic syndrome. Clin Diagn Lab Immunol 6 : 773, 1999
PubMed
4) Bitzan M, Moebius E, Ludwig K et al : High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome. J Pediatr 119 : 380-385, 1991
PubMed
5) Uemura O, Honda M, Matsuyama T et al : Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children : a multicenter study. Clin Exp Nephrol 15 : 694-699, 2011
PubMed
6) Kidney Disease : Improving Global Outcomes Acute Kidney Injury Work Group ; Kidney International. suppl 2 : 2012, p1-138
 
7) Loirat C, Fr6meaux-Bacchi V : Orphanet f Rare Dis 60 : 2011 doi : 10. 1186/1750-1172-6-60
 
8) Ake JA, Jalacic S, Ciol MA et al : Relative nephroprotection during Escherichia coli O157 : H7 infections : association with intravenous volume expansion. Pediatrics 115 : e673-e680, 2005
PubMed
9) Honda T, Ogata S, Mineo E et al : A novel strategy for hemolytic uremic syndrome : successful treatment with thrombomodulin α, Pediatrics 131 : e928-e933, 2013
 
10) Nathanson S, Kwon T, Elmaleh M et al : Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5 : 1218-1228, 2010
PubMed
11) 佐多徹太郎 : 厚生労働省科学研究費補助金厚生労働省科学特別研究事業「EHEC/O111食中毒事例における疫学的・細菌学・臨床研究」平成23年度総括・分担研究報告書.
 
12) Tayler CM, Machin S, Wigmore SJ et al : Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom, Br J Haematol 148 : 37-47, 2009
 
13) Ariceta G, Besbas N, Johnson S et al : Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24 : 687-696, 2011
 
14) Noris M, Remuzzi G : Atypical hemolytic-uremic syndrome. N Engl J Med 361 : 1676-1687, 2009
PubMed
15) Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al : Eculizumab in severe Shiga-toxin-associated HUS, N Engl J Med 354 : 2561-2563, 2011
 
16) Menne J, Nitschke M, Stirlgele et al : Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104 : H4 induced haemolytic uraemic syndrome : case-control study. BMJ 345 : 4565, 2012
 
P.210 掲載の参考文献
1) Moschcowitz E : Hyaline thrombosis of the terminal arterioles and capillaries : a hitherto undescribed disease. Proc NY Pathol Soc 24 : 21-24, 1924
 
2) Amorosi EL, Ultmann JE : Thrombotic thrombocytopenic purpura : report of 16 cases and review of the literature. Medicine 45 : 139-159, 1966
 
3) Moake JL, Rudy CK, Troll JH et al : Unusually large plasma factor VIII : von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura, N Engl J Med 307 : 1432-1435, 1982
PubMed
4) Furlan M, Robles R, Galbusera M et al : von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 : 1578-1584, 1998
PubMed
5) Kinoshita S, Yoshioka A, Park YD et al : Upshaw-Schulman syndrome revisited : A concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 41 : 101-108, 2001
 
6) Zheng XL, Chung D, Takayama TK et al : Structure of von Willebrand factor cleaving protease (ADAMTS 13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276 : 41059-41063, 2001.
 
7) Uemura, M, Tatsumi K, Matsumoto M, et al : Localization of ADAMTS 13 to the stellate cells of human liver. Blood 106 : 922-924, 2005
 
8) Soejima K, Matsumoto M, Kokame K et al : ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 102 : 3232-3237
 
9) Levy GG, Nichols WC, Lian AC et al : Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 : 488-494, 2001
 
10) Matsumoto M, Kokame K, Soejima K et al : Molecular characterization of ADAMTS 13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 103 : 1305-1310, 2004
 
11) Kokame K, Matsumoto M, Soejima K et al : Mutations and common polymorphisms in ADAMTS 13 gene responsible for von Willebrand factor-cleaving Protease activity. Proc Natl Acad Sci U S A 99 : 11902-11907, 2002
 
12) Kokame K, Aoyama Y, Matsumoto M et al : Inherited and de novo mutation of ADAMTS 13 in a patient with Upshaw-Schulman syndrome. J Thromb Haemost 6 : 213-215, 2008
 
13) Fujimura Y, Matsumoto M, Yagi H et al : von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 75 : 25-34, 2002
PubMed
14) Allford SL, Hunt BJ, Rose P et al : Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias, Br J Hematol 120 : 556-573, 2003
 
15) 金子仁臣, 松本雅則, 岡本浩平ほか : RituximabとVincristineの併用が奏功した難治性血栓性血小板減少性紫斑病. 臨床血液 48 : 144-147, 2007
 
16) Bobbio-Pallavicini E, Gugliotta L, Centurioni R et al : Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of randomized multicenter traial by the Italian cooperative group for TTP. Haematologica 82 : 429-435, 1997
 
17) Yagi H, Yamaguchi N, Shida Y et al : Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS 13 activity. Eur J Pharmacol 691 : 151-155, 2012
 
18) Matsuyama T, Kuwana M. Matsumoto M et al : Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases, Thromb Haemost 102 : 371-378, 2009
PubMed
19) Fujimura Y, Matsumoto M : Registry of 919 patients with thrombotic microangiopathies across Japan : database of Nara Medical University during 1998-2008. Intern Med 49 : 7-15, 2010
PubMed
P.224 掲載の参考文献
1) Raghu G, Collard HR, Egan JJ et al ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement ; idiopathic pulmonary fibrosis ; evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 : 788-824, 2011
PubMed
2) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編 : 特発性間質性肺炎-診断と治療の手引き 改訂第2版. 南江堂, 東京, 2011
 
3) Noth I, Anstrom KJ, Calvert SB et al : A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 186 : 88-95, 2012
PubMed
4) Raghu G : Idiopathic pulmonary fibrosis ; new evidence and an improved standard of care in 2012. Lancet 380 : 699-701, 2012
 
5) Park SH, Saleh D, Giaid A et al ; Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Anz/Respir Crit Care Med 156 : 600-608, 1997
 
6) Otsuka M, Takahashi H, Shuratori M et al : Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 59131-38, 2004
 
7) Senoo T, Hattori N, Tanimoto T et al : Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 65 : 334-340, 2010
PubMed
8) Papaioannou AI, Kostikas K, Kollia K et al : Clinical implication for vascular endothelial growth factor in the lung ; friend or foe? Respir Res 7 : 128, 2006
PubMed
9) 桑野和善, 皆川俊介, 荒屋潤 : 分子病態から見た肺線維症. 日内会誌 98 : 1134-1139, 2009
 
10) Kotani I, Sato A, Hayakawa H et al : Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 77 : 493-504, 1995
PubMed
11) Hubbard RB, Smith C, Le Jeune I et al : The association between idiopathic pulmonary fibrosis and vascular disease. Am J Respir Crit Care Med 178 : 1257-1261, 2008
PubMed
12) Nathan SD, Barnett SD, Urban BA et al : Pulmonary embolism in idiopathic pulmonary fibrosis transplarlt recipients. Chest 123 : 1758-1763, 2003
PubMed
13) Kubo H, Nakayama K, Yanai M et al : Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128 : 1475-1482, 2005
PubMed
14) Yard BA, Chonanopoulos E, Herr D et al : Regulation of endothelin-1 and transforming growth factor-β1 production in cultured proximal tubular cells by alubumin and heparin sulphate glycosaminoglycans. Nephrol Dial Transplant 16 : 1769-1775, 2001
 
15) Markart P, Nass R, Ruppert C et al : Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. J Aerosol Med Plu Drug Deliv 23 : 161-172, 2010
 
16) 吉村邦彦, 中谷龍王, 中森祥隆ほか : 特発性間質性肺炎の急性増悪に関する臨床的検討ならびに考察. 日胸疾会誌 22 : 1012-1020, 1984
 
17) Kondoh Y, Taniguchi H, Kawabata Y et al : Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103 : 1808-1903, 1993
PubMed
18) Collard HR, Moore BB, Flaherty KR et al : Acute exacerbations of idiopathic pulmonary fibrosis, Am J Respir Crit Care Med 176 : 636-643, 2007
PubMed
19) 谷口博之, 近藤康博 : 特発性肺線維症の急性増悪の新しい診断基準について. 厚生労働科学研究費補助金難治性疾患克服研究事業びまん性肺疾患に関する調査研究班平成15年度研究報告書. 2004, p114-119
 
20) Fujimoto K, Taniguchi H, Johkoh T et al : Acute exacerbation of idiopathic pulmonary fibrosis ; high-resolution CT scores predict mortality. Eur Radiol 22 : 83-92, 2012
PubMed
21) Azuma A, Nukiwa T, Tsuboi E et al : Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 : 1040-1047, 2005
PubMed
22) Taniguchi H, Ebina M, Kondoh Y et al : Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Ezar Respir J 35 : 821-829, 2010
 
23) Richeldi L, Costabel U, Selman M et al : Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365 : 1079-1087, 2011
PubMed
24) Ware LB, Bastarache JA, Wang L : Coagulation and fibrinolysis in human acute lung injur-New therapeutic target? Keio J Med 53 : 142-149, 2005
 
25) Ware LB, Fang X, Matthay MA : Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 285 : L514-L521, 2003
PubMed
26) 渡辺憲弥, 田島俊児, 田中淳一ほか : 急速に進行する間質性肺炎に対する抗凝固療法併用の有効性についての検討. 日呼吸会誌 49 : 407-412, 2011
Medical*Online
27) Yamakawa K, Fujimi S, Mohri T et al : Tretment effect of recombinant human soluble thrombomodulin in patients with severe sepsis ; a historical study. Critical Care 15 : R123, 2011
 
28) Uchiba M, Okajima K, Murakami K et al : Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 271 : L470-L475, 1996
PubMed
29) Ogawa Y, Yamakawa K, Ogura H, et al : Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 72 : 1150-1157, 2012
PubMed
30) Vincent JL, Ramesh MK, Ernest D et al : A randomized, double-blind, placebo-controlled, Phase 2 b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41 : 2069-2079, 2013
 
31) Collard HR, Calfee CS, Wolters PJ et al : Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 299 : L3-L7, 2010
PubMed
32) Ebina M, Taniguchi H, Miyasho T et al : Gradual increase of high mobility group protein b 1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis. Pulm Med : 916486, 2011
 
33) 谷口博之, 近藤康博, 木村智樹ほか : 特発性肺線維症の急性増悪に対するリコンビナントトロンボモジュリンの有効性の検討, 厚生労働科学研究費補助金難治性疾患克服研究事業びまん性肺疾患調査研究, 平成24年度研究報告書. 2013, p265-268
 
P.245 掲載の参考文献
1) Colman Rw, Robboy SJ, Minna JD : Disseminated intravascular coagulation (DIC) : an approach, Am J Med 52 : 679-689, 1972
PubMed
2) Levi M, de Jonge E, van der Poll T, ten Cate H : Disseminated intravascular coagulation. Thromb Haemost 82 : 695-705, 1999
PubMed
3) Taylor FB Jr, Toh CH, Hoots WK et al : Scientific Subcommittee on Disseminated on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) : Towards definition, Clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-133e, 2001
 
4) Lebi M, Toh CH, Thachil J, Watson HG : Guidelines for the diagnosis and management of disseminated intravascular coagulation. British J Haematol 20 : 24-33, 2009
 
5) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 : 77-113, 2009
 
6) 朝倉英策 : DICの分類. Thromb Med 1 : 38-44, 2011
Medical*Online
7) Kobayashi T, Sumimoto K, Tokunaga N et al : Coagulation index to distinguish severe preeclampsia from normal pregnancy, Semin Thromb Hemos 28 : 495-500, 2002
 
8) Lau SY, Guild SJ, Barrett CJ et al : Tumor Necrosis Factor-Alpha, Interleukin-6, and lnterleukin-10 Levels are Altered in Preeclampsia : A Systematic Review and Meta-Analysis. Am J Reprod Immunol 70 : 412-427, 2013
 
9) Mutter WP, Karumanchi SA ; Molecular mechanisms of preeclampsia. Microvasc Res 75 : 1-8, 2008
PubMed
10) Ohkuchi A, Hirashima C, Matsubara S et al : Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia, Hypertension 58 : 859-866, 2011
PubMed
11) Myatt L, Clifton R, Roberts J et al : Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-ec1ampsia in a low-risk nulliparous patient population? BJOG 120 : 1183-1191, 2013
 
12) 真木正博, 寺尾俊彦, 池ノ上克 : 産科DICスコア. 産婦治療 50 : 119-124, 1985
 
13) Thachil J, Toh CH : Disseminated intravascUlar coagUlation in obstetric disorders and its acute hematological management. Blood Rev ee : 167-176, 2009
 
14) Bick RL : Disseminated intravascular coagulation : A review of etiology, pathophysiology, diagnosis, and management : guidelines for care. Clin Appl Thromb Hemost 8 : 1-31, 2002
PubMed
15) Takemitsu T, Wada H, Hatada T et al : Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 105 : 40-44, 2011
PubMed
16) 桜井康良, 内田倫子, 愛波淳子, 三村文昭 : 産科DIC二対する各診断基準 (急性期DIC診断基準, 改訂厚生省DIC診断基準. 国際血栓止血学会診断基準) シミュレーションによる比較. 麻酔58 : 732-738, 2009
 
17) Wada H, Hatada T, Okamoto K et al : Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol 85 : 691-694, 2010
PubMed
18) 和田英夫, 下仮谷雄二 : DICの診断と治療の新展開Thromb Med 1 : 32-37, 2011
 
19) Tsukimori K, Ochi H, Yumoto Y et al : Reversible posterior encephalopathy syndrome followed by MR angiography-documented cerebral vasospasm in preeclampsia-eclampsia : report of 2 cases. Cerebrovasc Dis 25 : 377-380, 2008
PubMed
20) 田坂玲子, 中本收, 本久智賀, 三田育子 : 子癇における遅発性脳血管攣縮を示す4症例 (会議録). 妊高誌 19 : 151-153, 2012
 
21) Abildgaard U, Heimdal K : Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP) : a review. Eur J Obstet Gynecol Reprod Biol 166 : 117-123, 2013
PubMed
22) Catanzarite VA, Seinberg SM, Mosley CA et al : Severe preeclampsia with fulminant and extreme elevation of aspartate aminotransferase and lactate dehydrogenase levels : high risk for maternal death. Am J Perinatol 12 : 310-313, 1995
 
23) Hulstein JJ, van Runnard Heimel PJ, Franx A et al : Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Hemost 4 : 2569-2575, 2006
 
24) Koenig M, Roy M, Baccot S et al : Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antipho-sphoiipid syndrome) associated with HELLP syndrome. Clin Rheumatol 24 : 166-168, 2005
PubMed
25) Wada H, Thachil J, Di Nisio M et al ; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis : Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost : 2013. doi : 10. 1111/jth, 12155
 
26) Sakuragawa N, Hasegawa H. Maki M et al : Clinical evaluation of lowmolecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) ; a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 72 : 475-500, 1993
 
27) Nishiyama T, Matsukawa T, Hanaoka K : Is protease inhibitor a choice for the treatment of pre-or mild disseminate coagulation? Crit Care Med 28 : 1419-1422, 2000
PubMed
28) 鈴木宏治, 竹谷浩之 : 凝固線溶系-凝固系の最近の進歩. Thromb Med 1 : 13-20, 2011
 
29) Andersson U, Wang H, Palmblad K et al : High mobility group 1 protein (HMG-1) stimulates proinfiammatory cytokine synthesis in human monocytes. J Exp Med 192 : 565-570, 2000
 
30) Holmlund U, Wahamaa H, Bachmayer N et al : The novel inflammatory cytokine high mobility group box protein 1 (HMGB 1) is expressed by human term placenta. Immunology 122 : 430-437, 2007
PubMed
31) Wang B, Koga K, Osuga Y et al : High mobility group box 1 (HMGB 1) levels in the placenta and in serum in preeclampsia. Am J Reprod Immunol 66 : 143-148, 2011
PubMed
32) Marti-Carvajal AJ, Comunian-Carrasco G, Peria-Marti GE : Haematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum. Cochrane Database Syst Rev : CD008577, 2011. doi 10, 1002/14651858. CD 008577. pub 2
 
33) Ikezoe T, Ikenoue N, Uchikawa N et al : Use of recombinant human soluble thrombomodulin in the management of HELLP syndrome complicated by DIC. Thromb Res 126 : e238-e240, 2010
PubMed
34) 中本收, 田坂玲子, 本久智賀 : 遺伝子組換えトロンボモジュリン (rTM) 注射薬によって妊娠高血圧腎症重症の分娩後HELLP症候群病態の軽快に寄与できた5症例, 日産誌 64 : 528, 2012
 
35) Duhl AJ, Paidas MJ, Ural SH et al : Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy : consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 197 : 457, e1-e21, 2007
 
36) Lindqvist P, Dahlback B, Marsal K : Throm-botic risk during pregnancy : a population study, Obstet Gynecol 94 : 595-599, 1999
 
37) Paidas MJ, Ku DW, Arkel YS : Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome. Clin Perinatol 31 1783-805, 2004
 
38) National collaborating Center for Women's and Children's Health : the management of hypertensive disorders during pregnancy. NICE clinical Guidance, UK, 2010 (revised reprint 2011) http://www.nice.org.uk/nicemedia/live/13098/50475/50475.pdf
 
39) Mello G, Parretti E, Fatini C et al : Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-coverting enzyme DD women. Hypertension 45 : 86-91, 2005
 
40) Horlocker TT, Wedel DJ, Benzon H, et al : Regional anesthesia in the anticoagulated patient : defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 28 : 172-197, 2003
PubMed
41) James A : Committee on Practice Bulletins-Obstetrics, Practice bulletin no. 123 : thromboembolism in pregnancy. Obstet Gynecol 118 : 718-729. 2011
 
P.256 掲載の参考文献
1) Miyakis S, Lockshin MD, Atsumi T et al. Internatlonal consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 : 295-306, 2006
 
2) Atsumi T, Ieko M Bertolaccini ML et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43 : 1982-1993, 2000
PubMed
3) Brandt JT, Barna LK, Triplett DA : Laboratory identification of lupus anticoagulants : results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH, Thromb Haemost 74 : 1597-1603, 1995
 
4) Atsumi T, Amerlgual O, Yasuda S et al : Antiprothrombin antibodies--are they worth assaying? Thromb Res 114 : 533-538, 2004
 
5) Yasuda S, Tsutsumi A, Chiba H et al : β2-glycoprotein I deficiency : prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 152 : 337-346, 2000
 
6) Bohgaki M, Atsumi T, Yamashita Y et al : The p 38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2 Glycoprotein I antibodies. Int Immunol 16 : 1633-1641, 2004
 
7) Girardi G, Redecha P, Salmon JE : Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation, Nature medicine 10 : 1222-1226, 2004
PubMed
8) Oku K Atsumi T, Bohgaki M et al : Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68 : 1030-1035, 2009
PubMed
9) Khamashta MA, Cuadrado MJ, Mujic F et al l The management of thrombosis in the antiphospholipid-antibody syndrome. N EnglJ Med 332 : 993-997, 1995
 
10) Alarcon-Segovia D, Boffa MC. Branch W et al : Prophylaxis of the antiphospholipid syndrome : a consensus report. Lupus 12 : 499-503, 2003
PubMed
11) 小池隆夫 : 抗リン脂質抗体症候群の治療指針案について. 厚生省特定疾患対策研究事業, 自己免疫疾患の病因・病態解析と新たな治療法に関する研究報告書, 2002, p135-137
 
12) Garcia DA, Khamashta MA, Crowther MA : How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome : a case-based review, Blood 110 : 3122-3127, 2007
PubMed
13) Mak A, Cheung MW, Cheak AA et al : Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies : a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 49 : 281-288, 2010
PubMed
14) Shapira I, Andrade D, Allen SL et al : Brief report : induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis Rheum 64 : 2719-2723, 2012
PubMed
15) Pierangeli SS, Erkan D : Antiphospholipid syndrome treatment beyond anticoagulation : are we there yet? Lupars 19 : 475-485, 2010
 
16) Pierangeli SS, Espinola RG, Liu X et al : Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circulation research 88 : 245-250, 2001
PubMed
17) Erre GL, Pardini S, Faedda R et al : Effect of rituximab on clirlical and laboratory features of antiphospholipid syndrome : a case report and a review of literature, Lupus 17 : 50-55, 2008
 
P.273 掲載の参考文献
1) Toussaint S, Gerlach H : Activated protein C for sepsis. N Engl J Med 361 : 2646-2652, 2009
PubMed
2) Kumar G, Kumar N, Taneja A et al : Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 140 : 1223-1231, 2011
PubMed
3) Bernard GR, Vincent JL, Laterra PF et al : Efficacy and safety of recombinant human activated proteinc C for severe sepsis, N Eng J Med 344 : 699-709, 2001
 
4) Warren BL, Eid A, Singer P et al : High-dose antithrombin III in severe sepsis, A randomized controlled trial. JAMA 281 : 1869-1878, 2001
 
5) Abraham E, Reinhart K, Opal S et al : Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A rondomized controlled trial. JAMA 290 : 238-247, 2003
 
6) Levi M, de Jonge E, van der Poll T, ten Cate H : Disseminated intravascular coagulation. Thromb Haemost 82 : 695-705, 1999
PubMed
7) Taylor FB Jr, Toh C, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001
 
8) 丸藤哲, 早川峰司, 星野弘勝 : DIC概念の変遷. 日本救急医学会・日本血栓止血学会合同委員会提唱「救急領域のDIC診断基準 (案) 」成立とその過程, 救急医学 28 : 759-765, 2004
 
9) Coughlin SR : Thrombin signaling and protease-activated receptors. Nature 407 : 258-264, 2000
PubMed
10) Crowther MA, Marshall JC : Continuing challenges of sepsis research. 286 : 1894-1896, 2001
PubMed
11) Angus DC, Crowther MA : Unraveling severe sepsis. Why did OPTIMIST fail and what's next? JAMA 2901256-258, 2003
 
12) Taylor FB Jr, Toh C, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001
 
13) Ogura H, Gando S, Saitoh D et al : Epidemiology of severe sepsisin Japanese intensive care units ; a prospective multicenter study. J Infect Chemother 20 : 157-162, 2014
 
14) Kienast J, Juers M, Wiedermann CJ et al : Treatment effects of highdose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation, J Thromb Haemost 4 : 90-97, 2006
PubMed
15) Gando S, Saitoh D, Ogura H et al : Japanese Association for Acute Medicine Disseminated Intravascu! ar Coagulation (JAAM DIC) Study Group. Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis. Thromb Res 123 : 715-718, 2009
 
16) Dellinger RP, Levy MM, Carlet JM et al : Surviving Sepsis Campaign : international guidelines for management of severe sepsis and septic shock. lntensive Care Med 34 : 17-60, 2008
 
17) Russell JA : Management of sepsis. N Engl J Med 355 : 1699-1713, 2006
PubMed
18) Bernard GR, Vincent JL, Laterra PF et al : Ethcacy and safety of recombinant human activated proteinc C for severe sepsis. N Eng J Med 344 : 699-709, 2001
 
19) Warren BL, Eid A, Singer P et al : High-dose antithrombin III in severe sepsis. A randomized controlled trial. IAMA 281 : 1869-1878, 2001
 
20) Abraham E, Reinhart K, Opal S et al : Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis, A rondomized controlled trial, JAMA 290 : 238-247, 2003
 
21) http://www.uptodate.com/contents/clinical-features-diagnosis-and-treatment-of-disseminated-intravascular-coagulation-inadults?source=searchresult&search=dic&selectedTitle=1%7E150
 
22) Wada H, Asakura H, Okamoto K et al : Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 125 : 6-11, 2010
PubMed
23) Levi M, Toh CH, Thachil J et al : Guidelines for the diagnosis and management Of diSSeminated intraVaSCUIar COagUlatiOn. Br J Haematol 20 : 24-33, 2009
 
24) Iba T, Asakura H : Comparison between British and Japanese guidelines fo the diagnosis and treatment of disseminated intravascular coagulation, Br J Haematol 49 : 461-462, 2010
 
25) http://www.jsicm/org/SepsisJapan2012.pdf
PubMed
26) Gando S, Wada H, Asakura H et al : Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill Patients. Clin Appl Thromb Hemost 11 : 71-76, 2005
PubMed
27) Gando S, Iba T, Eguchi Y et al : Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group : A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria, Crit Cαre Med 34 : 625-631, 2006
 
28) Gando S, Saitoh D, Ogura H et al : Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group : Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria fOr critically ill patients : Results of a multicenter, prospective survey. Crit Car Med 36 : 145-150, 2008
 
29) Kushimoto S, Gando S, Saitoh D et al : Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria : Comparison between sepsis and trauma. Thromb Haemost 100 : 1099-1105, 2008
PubMed
30) 久志本成樹, 池田寿昭, 射場敏明ほか : DIC症例の全体像と病態別特徴, 日救急医会誌 18 : 246-251, 2007
 
31) Levi M, Meijers JC : DIC : Which laboratory tests are most useful. Blood Reviewers 25 : 33-37, 2011
 
32) Gando S, Iba T, Eguchi Y et al : A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Cαre Med 34 : 625-631. 2006
 
33) Dellinger RP, Levy MM, Carlet JM et al : Surviving Sepsis Campaign : international guidelines for management of severe sepsis and septic shock : 2008. fntensive Care Med 34 : 17-60, 2008
PubMed
34) 丸山征郎, 坂田洋一, 和田英夫ほか : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日本血栓止血学会誌 20 : 77-113, 2009
 
35) Wada H, Asakura H, Okamoto K et al : Expert consensus for the treatment of disseminated intravascular coagulation in Japan, Thromb Res 125 : 6-11, 2010
PubMed
36) Kienast J, Juers M, Wiedermann CJ et al : Treatment effects of highdose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4 : 90-97, 2006
PubMed
37) wiedermann CJ, Hoffmann JN, Juers M et al : High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death : Effcacy and safety. Crit Care Med 34 : 285-292, 2006
 
38) Wiedermann CJ, Kaneider NC : Asystematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis l71521-526, 2006
 
39) Fourrier F, Chopin C, Huart JJ et al : Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104 : 882-888, 1993
PubMed
40) Baudo F, Caimi TM, de Cataldo F et al : Antithrombin III replacement therapy in patients with sepsis and/or postsurgical complications : acontrolled double-blind, randomized, multicenter study. Intensive Care Med 24 : 336-342, 1998
PubMed
41) Levi M, Toh CH, Thachil J, Watson HG : Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology, Br J Haematol 145 : 24-33, 2009
PubMed
42) Higuchi T, Nakamura T, Kakutani H et al : Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor, Biol Pharm Bull 32 : 179-185, 2009
PubMed
43) Ito T, Kawahara K, Okamoto K et al : Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28 : 1825-1830, 2008
PubMed
44) Saito H, Maruyama I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5 : 31-41, 2007
PubMed
45) Yamakawa K, Fujimi S, Mohri T et al l Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis : ahistorical control study. Crit Care 15 : R123, 2011
 
46) 丸藤哲, 和田英夫, 長谷川友紀ほか : 救急領域のDIC診断基準 (案) 中間報告, 日救急医会誌14 : 280-287, 2003
 
47) 丸藤哲, 射場敏明, 江口豊ほか : 急性期DIC診断基準多施設共同試験結果報告. 日救急医会誌 16 : 188-202, 2005
 
48) 丸藤哲, 池田寿昭, 石倉宏恭ほか : 急性期DIC診断基準で作成されたDIC症例の特徴と予後 18 : 237-272. 2007
 
49) 齋藤大蔵, 岡本好司, 真弓俊彦ほか : 第二次多施設共同前向き試験結果報告 : 治療効果の分析. 日救急医会誌 18 : 262-272, 2007
 
50) Warren BL, Eid A, Singer P et al : High-dose antithrombin III in severe sepsis, A randomized controlled trial, JAMA 286 : 1869-1878, 2001
PubMed
51) Kienast J, Juers M, Wiedarlnann CJ et al : Treatment effects of highdose antithrombin III without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation, J ThrombHaemost 3 : 1-8, 2005
 
52) Gando S, Saitoh D, lshikura H et al : A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 17 : R297, 2013
 

Chapter 6 Question & Answer

P.284 掲載の参考文献
1) Warren BL, Eid A, Singer P et al : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 286 : 1869-1878, 2001
PubMed
2) Kienast J, Juers M, Wiedermann CJ et al : Treatment effects of high-dose antithrombin without concomitant heparin in patierlts with severe sepsis with or without disseminated intravascular coagulation. J Thrombo Haemost 4 : 90-97, 2006
 
3) Ito T, Kawahara K, Okamoto K et al : Proteolytic cleavage of high mobility group box l protein by thrombin-thrombomodulin complexes. Arterioscler Thrombo Vasc Biol 28 : 1825-1830, 2008
 
4) Saito H, Maruyama I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III randomized, double-blind clinical trial, J Thromb Haemost 5 : 31-41, 2007
PubMed
5) 川杉和夫 : 急性骨髄性白血病に合併したDICに対するrTM製剤の効果. 血液・腫瘍科60 : 526-531, 2010
 
P.292 掲載の参考文献
1) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference : definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 : 864-874, 1992
PubMed
2) Bone RC, Balk RA, Cerra FB et al : Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 : 1644-1655, 1992
PubMed
3) Marshall JC : SIRS and MODS : What is their relevance to the science and practice of intensive care? Shock 14 : 586-589, 2000
 
4) Vincent JL : Dear SIRS, rm sorry to say that I don't like you…. CritCare Med 25 : 372-374, 1997
 
5) Levy MM, Fink MP, Marshall JC et al : SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS Interrlational Sepsis Definitions Conference. Crit Care Med 31 : 1250-1256, 2003
 
6) Zhao H, Heard SO, Mullen MT et al : An evaluation of the diagnostic accuracy of the 1991 American College of Chest Physicians/Society of Critical Care Medicine and the 2001 Society of Critical Care Medicine/European Society of Intensive Care Medicine/American College of Chest Physicians/American Thoracic Society/Surgical Infection Society sepsis definition. Crit Care Med 40 : 1700-1706, 2012
PubMed
7) Luheshi GN : Cytokines and fever. Mechanisms and sites of action. Ann N Y Acad Sci 856 : 83-89, 1998
PubMed
8) Okabayashi K, Wada H, Ohta S et al : Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hemαtol 76 :225-229, 2004
 
9) Bernard GR, Artigas A, Brigham KL et al : The American-European Consensus Conference on ARDS. Definifitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care conference 149 : 818-824, 1994
 
10) 小関一英, 遠藤重厚, 丸藤哲ほか : 急性期DIC診断基準の考え方. 救急医学 30 : 115-119, 2006
 
11) Iba T, Gando S, Murata A et al : Predicting the severity of systemic inflammatory response syndrome (SIRS) -associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 63 : 1093-1098, 2007
PubMed
P.299 掲載の参考文献
1) Gando S, Iba T, Eguchi Y et al : Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group, Amulticenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : Comparing current criteria. Crit Care Med 34 : 625-631, 2006
 
2) Wada H, Wakita Y, Nakase T et al : Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 74 : 848-852, 1995
 
3) Dellinger RP. Levy MM, Rhodes A et al : Surviving sepsis campaign 1 international guidelines for management of severe sepsis and septic shock : 2012, Crit Care Med 41 : 580-637, 2013
PubMed
4) 丸山征郎, 坂田洋一, 和田英夫ほか : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日本血栓止血学会誌 20 : 77-113, 2009
 
5) Levi M, Toh CH, Thachil J et al : Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards irl Haematology. Br J Haematol l45 : 24-33, 2009
 
6) Di Nisio M, Baudo F, Cosmi B et al : Diagnosis and treatment of disseminated intravascular coagulation : Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res l29 : e177-e184, 2012
 
7) Warren BL, Eid A, Singer P et al : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 286 : 1869-1878. 2001
PubMed
8) Kienast J, Juers M, Wiedermann CJ et al : Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4 : 90-97, 2006
 
9) 丸藤哲, 齋藤大蔵, 石倉宏恭ほか : 急性期DIC診断基準で診断された敗血症性DICに対するアンチトロンビンの効果. 日救急医会誌 24 : 105-113, 2013
 
10) Bernard GR, Vincent JL, Laterre PF et al : Ethcacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 : 699-709, 2001
PubMed
11) Ranieri VM, Thompson BT, Barie PS et al : Drotrecogin alfa (activated) in adults with septic shock, N Engl J Med 36612055-2064, 2012
PubMed
12) Fourrier F : Severe sepsis, coagulation, and fibrinolysis : dead end or one way? Crit Care Med 40 : 2704-2708, 2012
PubMed
13) Saito H, Maruyama I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J ThrombHaemost 5131-41, 2007
 
14) Yamakawa K, Fujimi S, Mohri T et al : Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis : a historical control study. Crit Care 15 : R123. 2011
PubMed
P.305 掲載の参考文献
1) DeLeve LD, Shulman HM, McDonald GB : Toxic inlury to hepatic sinusoids : sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22 : 27-42, 2002
PubMed
2) McDonald GB, Hinds MS, Fisher LD et al : Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation : a cohort study of 355 patients. Ann Intern Med 118 : 255-267, 1993
PubMed
3) Jones RJ, Lee KS, Beschorner WE et al : Venoocclusive disease of the liver following bone marrow transplantation. TransPlantαtion 44 : 778-783, 1987
 
4) Carreras E, Diaz-Beya M, Rosinol L et al : The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 17 : 1713-1720, 2011
PubMed
5) Hashiguchi M, Okamura T, Yoshimoto K et al : Demonstration of reversed flow in segmental branches of the portal vein with hand-held color Doppler ultrasonography after hematopoietic stem cell transplantation. Bone Marrow Transplant 36 : 1071-1075, 2005
PubMed
6) Cutler C, Kim HT, Ayanian S et al : Prediction of veno-occlusive disease using biomarkers of endothelial inlury. Biol Blood Marrow Transplant 16 : 1180-1185, 2010
PubMed
7) Pidala J, Kim J, Anasetti C et al : Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 3 : 36, 2010
PubMed
8) Tay J, Tinmouth A, Fergusson D et al : Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13 : 206-217, 2007
PubMed
9) Imran H, Tleyjeh IM, Zirakzadeh A et al : Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation : a systematic review and meta-analysis. Bone Marrow Transplant 37 : 677-686, 2006
PubMed
10) Yakushijin K, Okamura A, Ono K et al : Defibrotide therapy for patients with sinusoidal obstruction syndrome after hematopoietic stem cell transplantation. Rinsho Ketsueki 50 : 3-8, 2009
PubMed
11) Palmer KJ, Goa KL : Defibrotide, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 45 : 259-294, 1993
PubMed
12) Richardson PG, Soiffer RJ, Antin JH et al : Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation : a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 16 : 1005-1017, 2010
PubMed
13) Chopra R, Eaton JD, Grassi A et al : Defibrotide for the treatment of hepatic veno-occlusive disease : results of the European compassionate-use study. Br J Haematol 111 : 1122-1129, 2000
PubMed
14) Corbacioglu S, Cesaro S, Faraci M et al : Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation : an open-label, phase 3, randomised controlled trial. Lancet 379 : 1301-1309, 2012
PubMed
15) Zhang L, Wang Y, Huang H : Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation : a systematic review. Clin Transplant 26 : 511-519, 2012
PubMed
16) Ikezoe T, Togitani K, Komatsu N et al : Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 45 : 783-785, 2010
PubMed
17) Yamamoto S, Yagawa A, Toyama D et al : Successful treatment of hepatic sinusoidal obstructive syndrome after hematopoietic stem cell transplantation in a child using recombinant thrombomodulin. Acta Haematol 29 : 62-64, 2013
 
18) Nomura S, Ishii K, Inami N et al : Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation. Biol Blood Marrow Transplant 14 : 766-774, 2008
PubMed
19) Tsubokura M, Yamashita T, Inagaki L et al : Fatal intracranial hemorrhage following administration of recombinant thrombomodulin in a patient after cord blood transplantation, Bone Marrow Transplant 46 : 1030-1031, 2011
 
20) Ruutu T, Barosi G, Benjamin RJ et al : Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy : results of a consensus process by an International Working Group, Haematologica 92 : 95-100, 2007
 
21) Sakai M, Ikezoe T, Bandobashi K et al : Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 45 : 803-805, 2010
PubMed
22) Luft T, Dietrich S, Falk C et al : Steroid-refractory GVHD : T-cell attack within a vulnerable endothelial system. Blood 118 : 1685-1692, 2011
PubMed
P.319 掲載の参考文献
1) Montgolnery RR, Scott JP : Disseminated intravascular coagulation (Consumptive coagulopathy) (Behrman RE, Kliegman RM, Jenson HB eds). WB Saunders Company, St Louis, 1999, p 1519-1520
 
2) Scott JP, Montgomery RR : Hematologic and thrombotic disease (Kliegman RM eds), WB Sanuders Company, St Louis, 2007, p2060-2089
 
3) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDICのエキスパートコンセンサス. 血栓止血誌 20 : 77-113, 2009
 
4) Sakuragawa N, Hasegawa H, Maki M et al : Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) : A multicenter co-operative double-blind trial in comparison with heparin, Thromb Res 72 : 475-500, 1993
PubMed
5) 中村外士雄, 有吉宣明, 朝倉昭雄ほか : 小児のDICに対するメシル酸ガベキサートの投与効果. 日小血会誌 1 : 75-83, 1987
 
6) 塙坂八重, 高橋幸博, 川口千晴ほか : 新生児の播種性血管内凝固に対するメシル酸ナファモスタット (Futhan) の治療効果-メシル酸ガベキサート (FOY) との比較-. 日小血会誌 18 : 23-28, 2004
 
7) 白幡聡, 白川嘉継, 吉田雄司ほか : 新生児のDICに対するアンチトロンビン III 濃縮製剤の有用性, 新生児誌 29 : 98-105, 1993
 
8) Warren BL. Eid A, Singer P et al : High-dose antithrombin III in severe sepsis : A randomized controlled trial. IAMA 286 : 1869-1878, 2001
 
9) Kienast J, Juers M, wiedermann CJ et al : Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 4 : 90-97, 2006
 
10) Saito H, Maruyama I, Shimazaki S et al : Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravasucular coagulation : Results of a phase III, randomaized, double-blind clinical trial. J Thromb Haemost 5 : 31-41, 2007
 
11) Shirahata A, Takahashi H, Kitajima I et al : Recombinant soluble human thrombomodulin (thrombomodulin α) in the treatment of neonatal disseminated intravascular coagulation. Eur J Pediatr 173 : 303-311, 2014
 
12) Shirahata A, Mimuro J, Takahashi H et al : Post-marketing surveillance of recombinant human soluble thrombomodulin (thrombomodulin α) in pediatric patients with disseminated intravascular coagulation. Clin, Appl Thromb/Hemost. in press
 
P.324 掲載の参考文献
1) Taylor FB Jr, Toh CH, Hoots WK et al : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001
 
2) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日血栓止血会誌 20 : 77-113, 2009
 
3) Rangel-Frausto MS, Pittet D, Costigan M et al : The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 : 117-123, 1995
PubMed
4) Lopes JA, Jorge S, Resina C et al : Acute kidney injury in patients with sepsis : a contemporary analysis. Int J Infect Dis 13 : 176-181, 2009
PubMed
5) 内藤澄悦, 家子正裕, 吉田美香ほか : ヘパリン治療のモニタリングにおける種々のAPTT試薬およびヘパリン投与量の相関性に関する検討. 日本検査血液学会雑誌 13 : 160-166, 2012
 
6) Hayakawa M, Sawamura A, Yanagida Y et al : The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction. Shock 30 : 649-652, 2008
 
7) Nakashima M, Kanamaru M, Umemura K et al : Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol 38 : 40-44, 1998
PubMed
8) Tsuruta K, Kodama T, Serada M et al : Pharmacokinetics of recombinant human soluble thrombomodulin, thrombomodulin alfa in the rat. Xenobiotica 39 : 125-134, 2009
PubMed
9) Nakashima M, Uematsu T, Umemura K et al : A novel recombinant soluble human thrombomodulin, ART-123, activates the protein C pathway in healthy male volunteers. J Clin Pharmacol 38 : 540-544, 1998.
PubMed
10) Hayakawa M, Yamamoto H, Honma T et al : Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment. Shock 37 : 569-573, 2012
PubMed
P.332 掲載の参考文献
1) Hotchikiss RS, Karl IE : The Pathophysiology and Treatment of Sepsis. N Engl J Med 348 : 138-150, 2003
 
2) Hotchkiss RS, Swanson PE, Freeman BD et al : Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction, Crit Care Med 27 : 1230-1251, 1999
PubMed
3) Mort TC, Yeston NS : The relationship of pre mortem diagnoses and post mortem findings in a surgical intensive care unit, Crit Care Med 27 : 299-303, 1999
 
4) Blosser SA, Zimmerman HE, Stauffer JL : Do autopsies of critically ill patients reveal important findings that were clinically undetected? Crit Care Med 26 : 1332-1336, 1998
PubMed
5) Kreymann G, Grosser S, Buggisch P : Oxygen consumption and resting metabolic rate in sepsis, sepsis syndrome, and septic shock, Crit Care Med 21 : 1012-1019, 1993
PubMed
6) Brealey D, Brand M, Hargreaves I et al : Association between mitochondrial dysfunction arld severity and outcome of septic shock, Lancet 3601 219-223, 2003
 
7) Cinel I, Opal SM : Molecular biology of inflammation and sepsis : a primer. Crit Care Med 37 : 291-304, 2009
 
8) Kono H, Rock KL : How dying cells alert the imrnune system to danger. Nature Reviews Immunology 8 : 279-289, 2008
PubMed
9) Moore FA, Sauaia A, Moore EE et al : Postinjury Multiple Organ Failure : A Bimodal Phenomenon. J Trauma 40 : 510-512, 1996
 
10) Zhang Q, Raoof M, Chen Y et al : Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464 : 104-107, 2010
PubMed
11) Iyer SS, Pulskens WP, Sadler JJ et al : Necrotic cells trigger a sterile inflammatory response through the Nlrp 3 inflammasome, Proc Natl Acad Sci USA 106 : 20388-20393, 2009
 
12) Masters SL, Walsh PT : Release of the mitochondrial endosymbiont helps expain sterile inflammation. Proc Natl Acad Sci U S A 107: E32, 2010
 
13) Collins LV, Hajizadeh S, Holme E et al : Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J Leufeoc Biol 75 : 995-1000, 2004
PubMed
14) Crouser ED, Shao G, Julian MW et al : Monocyte activation by necrotic cells is promoted by mitochondrial proteins and fdrmyl peptide receptors. Crit Care Med 37 : 2000-2009, 2009
PubMed
15) Angus DC : Drotrecogin α (activated). ., a sad final fizzle to a rollercoaster party. Crit Care 16 : 107, 2012
 
16) Boomer JS, To K, Chang KC et al : Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure, JAMA 306 : 2594-2605, 2011
PubMed
17) Xiao W, Mindrinos MN, Seok J et al : A genomic storm in critically injured humans. J Exp Med 208 : 2581-2590, 2011
 

書評

最近チェックした商品履歴

Loading...